NCT07118306Recruiting
COPD Exacerbation Follow Up
A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 485 (estimated)
- First submitted
- 1 Aug 2025
- Start date
- 27 Feb 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Viz.ai, Inc.
- Diseases
- COPD
- NCT number
- NCT07118306
What you commit to
- Study type: Observational
- Planned participants: 485
- From 27 Feb 2026 to the primary completion date, Jul 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received a lung transplant.
Other illness
- Patients with advanced cancer.
Other
- Patients on bronchodilator inhaler monotherapy.
- Patients leaving against medical advice or expiring during hospitalization.
- Patients with tracheostomy.
- Discharge to hospice care.
- Transfer to another hospital.
Who the study is looking for
- Patients aged 40 years or older at the time of arrival to the emergency department.
- Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
- A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
- A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death.
- Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cooper University Health Care Coordinator of this site? Confirm its status | Cherry Hill | United States | Recruiting |
| Inova Fairfax Hospital Coordinator of this site? Confirm its status | Falls Church | United States | Not yet recruiting |
| Aurora St. Luke's Medical Center Coordinator of this site? Confirm its status | Milwaukee | United States | Not yet recruiting |
| Advocate Lutheran General Hospital Coordinator of this site? Confirm its status | Park Ridge | United States | Recruiting |
| Thomas Jefferson University Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.